Aurinia Pharmaceuticals 



#1203 – 4464 Markham Street

Victoria BC

V8Z 7X8


Member Sector: Biopharmaceuticals

Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.